David D. Schlaepfer

UC San Diego Health System — United States

Medicine · Health Sciences

78h-index27.9kcitations237works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cell Adhesion Molecules Research(167), Cellular Mechanics and Interactions(69), Protease and Inhibitor Mechanisms(44), Angiogenesis and VEGF in Cancer(26), Caveolin-1 and cellular processes(20)

Publications236 total

FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages
Cell Reports·2026Open Access
Ovarian Tumor FAK Inhibition Releases Omega-3 Fatty Acids Stimulating GATA6 Peritoneal Macrophage CXCL13 Production Enhancing Immunotherapy
2025Open Access
Discovery and structural identification of human endogenous retrovirus-K env monoclonal antibody: Uncovering viral epitopes in ovarian cancer
Gynecologic Oncology·2025
Liposomal Doxorubicin, but Not Platinum-Taxane, Supports MHC-II Expression and Immune Maturation in the Ovarian Tumor Microenvironment
Cancers·2025· 1 citedOpen Access
Inducible FAK loss but not FAK inhibition in endothelial cells of PYK2-null mice activates p53 tumor suppressor to prevent tumor growth
Molecular Biology of the Cell·2025· 4 cited
Figure 1 from Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma
2024Open Access
Figure 2 from Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma
2024Open Access
Figure 3 from Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma
2024Open Access
Figure 6 from Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma
2024Open Access
Figure 5 from Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma
2024Open Access
Data from Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma
2024Open Access
Figure 4 from Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma
2024Open Access
Figure 7 from Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma
2024Open Access
Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma
Cancer Research Communications·2024· 5 citedOpen Access
Inducible FAK Deletion but not FAK Inhibition in Endothelial Cells Activates p53 to Suppress Tumor Growth in PYK2-null Mice
2024Open Access
RAS/RAF/MEK mutated high-grade serous ovarian cancer susceptible to Raf inhibition in vitro but not in vivo
Gynecologic Oncology·2024
Focal adhesion kinase inhibitors as maintenance therapy in a homologous recombination repair proficient high-grade serous ovarian cancer murine model
Gynecologic Oncology·2024
Focal adhesion kinase signaling – tumor vulnerabilities and clinical opportunities
Journal of Cell Science·2024· 19 citedOpen Access
FAK, vinculin, and talin control mechanosensitive YAP nuclear localization
Biomaterials·2024· 38 citedOpen Access
Abstract B024: Maintenance therapy inhibition of ptk2 yields decreased disease in preclinical HRP/HRD models of recurrent HGSOC
Cancer Research·2024
page 1 of 12Next →

Frequent Co-authors

Ssang‐Taek Lim(9), Duško Ilić(8), Xiao Lei Chen(8), Tony Hunter(7), Christof R. Hauck(7), David A. Cheresh(7), Dwayne G. Stupack(7), Sean Uryu(7), Satyajit K. Mitra(5), David J. Sieg(5), Harry T. Haigler(5), Christine Jean(4), Datsun A. Hsia(4), Christine Lawson(4), Alok Tomar(4), Sara M. Weis(4), Caroline H. Damsky(3), Ju‐Ock Nam(3), Colin Walsh(3), Isabelle Tancioni(3)